Peter Allen
About Peter Allen
Peter Allen is a Research Associate II at the Broad Institute of MIT and Harvard, where he focuses on cancer biology and immunotherapy targets using large-scale CRISPR screens. He has a background in biology and computer science from the University of Pittsburgh and has held various internships in the field of research.
Work at Broad Institute
Peter Allen has been employed at the Broad Institute of MIT and Harvard since 2019. He currently holds the position of Research Associate II, a role he has maintained since 2022. His work is based in Cambridge, Massachusetts, where he focuses on utilizing large-scale CRISPR screens to investigate cancer biology and identify novel immunotherapy targets. He is part of the Tumor Immunotherapy Discovery Engine (TIDE) within the Manguso Lab, contributing to significant research in the field of cancer treatment.
Education and Expertise
Peter Allen earned his Bachelor’s Degree from the University of Pittsburgh, where he studied Biology, Computer Science, and Chinese from 2015 to 2019. His academic background provides him with a strong foundation in both biological sciences and computational methods, which are essential for his current research in cancer biology and immunotherapy. He completed his secondary education at Brookline High School from 2011 to 2015.
Previous Work Experience
Before joining the Broad Institute, Peter Allen gained experience as an Innovation Intern at Pitt sciVelo in 2018, where he worked for three months in the Greater Pittsburgh Area. Additionally, he served as a Summer Intern at Alkermes in 2016 for two months in Waltham, Massachusetts. These roles contributed to his understanding of the biotechnology sector and prepared him for his current research position.
Research Focus
In his role at the Broad Institute, Peter Allen specializes in large-scale CRISPR screens, which are instrumental in understanding the complexities of cancer biology. His research aims to discover new targets for immunotherapy, a rapidly evolving area in cancer treatment. By working in the Tumor Immunotherapy Discovery Engine (TIDE), he engages in innovative research that has the potential to impact therapeutic strategies for cancer patients.